BMJ Open

Protocol for Gut Bugs in Anorexia Nervosa: An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2022-070616
Article Type:	Protocol
Date Submitted by the Author:	07-Dec-2022
Complete List of Authors:	Wilson, Brooke; The University of Auckland, Liggins Institute Derraik, José; The University of Auckland, Liggins Institute; The University of Auckland, Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences Albert, Benjamin; The University of Auckland, Liggins Institute Leong, Karen; The University of Auckland, Liggins Institute Tweedie-Cullen, Ry; The University of Auckland, Liggins Institute Creagh, Christine; The University of Auckland, Liggins Institute Depczynski, Marysia; The University of Auckland, Liggins Institute Edwards, Taygen; The University of Auckland, Liggins Institute Vatanen, Tommi; The University of Auckland, Liggins Institute; University of Helsinki, Research Program for Clinical and Molecular Metabolism Thabrew, Hiran; The University of Auckland, Psychological Medicine; The University of Auckland, Te Ara Hāro, Centre for Infant, Child and Adolescent Mental Health Cutfield, Wayne; The University of Auckland, Liggins Institute O'Sullivan, Justin ; The University of Auckland, Liggins Institute
Keywords:	Eating disorders < PSYCHIATRY, MICROBIOLOGY, THERAPEUTICS, Transplant medicine < INTERNAL MEDICINE, GASTROENTEROLOGY

Protocol for Gut Bugs in Anorexia Nervosa

An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa

Brooke C. Wilson[a], José G. B. Derraik[a,b], Benjamin B. Albert[a], Karen S. W. Leong[a], Ry Y. Tweedie-Cullen[a], Christine Creagh[a], Marysia Depczynski[a], Taygen Edwards[a], Tommi Vatanen[a,c], Hiran Thabrew[d,e], Wayne S. Cutfield[a*], Justin M. O'Sullivan[a*]

a. Liggins Institute, University of Auckland, Auckland, New Zealand.
b. Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
c. Research Program for Clinical and Molecular Metabolism, University of Helsinki, Finland
d. Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.
e. Te Ara Hāro, Centre for Infant, Child and Adolescent Mental Health, University of Auckland, Auckland New Zealand.

***Joint Correspondence**
Professor Wayne Cutfield & Professor Justin O'Sullivan
Address: Liggins Institute, University of Auckland, Private Bag 92019, Auckland, New Zealand
Email: w.cutfield@auckland,ac,nz, justin.osullivan@auckland.ac.nz

Version
1

Word count (excludes abstract, tables, acknowledgements, author contributions, COI, references)
3940

ABSTRACT

Introduction: Individuals with anorexia nervosa (AN) harbour distinct gut microbiomes compared to healthy individuals, which are sufficient to induce weight loss and anxiety-like behaviours when transplanted into germ-free mice. We hypothesise that faecal microbiome transfer (FMT) from healthy donors would help restore the gut microbiome of individuals with AN, which in turn, may aid patient recovery.

Methods: We aim to conduct an open-label pilot study in 20 females aged 16-25 years who meet the DSM-5 criteria for AN and have a BMI 13-19 kg/m^2. We will recruit four healthy, lean, female donors, aged 18-32 years, who will undergo extensive clinical screening prior to stool donation. Faecal microbiota will be harvested from donors and double encapsulated in delayed release, acid-resistant capsules. All participants will receive a single course of 20 FMT capsules (five from each donor) which they can choose to take over two or four consecutive days. Stool and blood samples will be collected from participants over a period of three months to assess their gut microbiome profile, metabolome, intestinal inflammation, and nutritional status. Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT (Bray-Curtis dissimilarity). We will also monitor participants' body composition (DXA scans), eating disorder psychopathology, mental health, and assess their views on, and tolerability of, treatment. All adverse events will be recorded and reviewed by an independent data monitoring committee.

Ethics and dissemination: Ethics approval was provided by the Central Health and Disability Ethics Committee (Ministry of Health, New Zealand, 21/CEN/212). Results will be published in peer-reviewed journals and presented to both scientific and consumer group audiences.

Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12621001504808).

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This pilot trial investigates FMT as a therapy for gut microbiome restoration in young women with AN.
- This study has been co-designed in consultation with eating disorder specialists and recovered individuals to minimise participant harm and stress.
- The use of high-resolution shotgun metagenomic sequencing will allow for a comprehensive gut microbiome assessment and longitudinal tracking of donor strain engraftment.
- While we will monitor clinical features of AN throughout the trial, efficacy of FMT on clinical outcomes cannot be assessed due to its design without a control group.
- By focusing on young women with AN, study findings may not necessarily apply to the broader population of individuals with AN.

INTRODUCTION

Anorexia nervosa (AN) is a complex and debilitating eating disorder characterised by extremely restrictive eating behaviour, very low body weight, a fear of weight gain, and body image distortion [1]. AN has the highest mortality rate among psychiatric disorders (standardised mortality ratio of 5.86 [2]) and is often accompanied by comorbidities including anxiety, depression, autoimmune disorders, and functional gastrointestinal disorders [2–5]. AN usually begins in adolescence and is more common in women (lifetime prevalence of 1.4% compared to 0.2% in men [6]). While its exact aetiology is unclear, the development of AN likely stems from both environmental triggers [7] and genetic predisposition [8, 9]. In addition, emerging evidence suggests the gut microbiome might also be involved in AN as an important regulator of appetite, mood, and metabolism [10–13].

Multiple studies have shown that the gut microbiome is perturbed in individuals with AN compared to healthy individuals [14–20]. In particular, anorexia-associated microbiomes are typically less diverse [16, 17, 19] and contain proportionally more mucin-degrading bacterial species such as *Methanobrevibacter smithii* [14, 17, 18, 20]. Degradation of the intestinal mucus lining can lead to increased permeability and translocation of bacterial products into circulation [21, 22], both of which have been observed in AN [23–26].

While the gut microbiome alterations observed in AN are likely a consequence of severe caloric restriction and psychological stress, the gut microbiome itself has also been suggested to play a role in perpetuating symptoms of the disorder [27]. For example, individuals with AN have higher blood levels of caseinolytic-protease-B (ClpB), a protein produced by commensal gut species [26]. ClpB shares homology with the human anorexigenic α-melanocyte-stimulating hormone (a-MSH) and may therefore mimic its function to suppress appetite and increase energy expenditure [28].

A contributory role of the gut microbiome in AN symptomatology was demonstrated when germ-free mice were inoculated with the gut microbiome derived from either healthy human donors or donors with AN [29]. The mice who received the ‘AN microbiome’ showed reduced body weight and a concomitant reduction in food intake. Interestingly, when the ‘AN microbiome’ mice ate the same amount of food as the ‘healthy microbiome’ mice, they gained less weight suggesting they struggled to convert food into body mass [29]. Furthermore, the ‘AN microbiome’ mice had reduced serotonin levels and displayed anxiety-related and compulsive behaviours [29]. Collectively, these findings highlight the gut microbiome as a potential mediator of disease in AN and a suitable target for therapeutic intervention.

Current treatment approaches for AN are multidisciplinary and focus on nutritional rehabilitation, weight restoration, and cognitive behavioural therapy [30]. However, despite these efforts, approximately 30% of individuals will only partially recover from the disorder, with a further 20% maintaining a chronic course of illness over their lifetime [31]. Even after nutritional interventions and weight restoration, the gut microbiome in individuals with AN remains distinct from that of healthy individuals [16, 17], potentially contributing to relapse of symptoms [27]. Therefore, strategies designed to restore the gut microbiome in AN may be of clinical benefit when used in conjunction with current nutritional rehabilitation therapies, and warrant further investigation.

Faecal microbiome transfer (FMT) involves the transfer of gut microbiota from healthy donors to recipients with gut dysbiosis. This therapy has proven highly effective for treating recurrent *Clostridioides difficile* infections, and can rapidly restore the diversity and functions of the gut microbiome in these patients [32]. FMT has also been trialled in other disorders associated with less severe forms of gut dysbiosis, such as obesity [33–35], metabolic syndrome [36–39], inflammatory bowel disease [40], irritable bowel syndrome [41], and autism [42]. While FMT cannot cure these multi-faceted conditions, its ability to alter the gut microbiome has led to various therapeutic benefits among recipients including improvements in fat distribution [35], metabolic syndrome [35], insulin sensitivity [36, 37], intestinal permeability [43], gut inflammation [44], gastrointestinal symptoms [45], and social behaviours [42].

Given the role of the gut microbiome in regulating appetite, mood, and metabolism [10–12], restoring the gut microbiome in individuals with AN may act as a stepping stone towards improved patient recovery. There have been two published case reports of FMT in patients with AN [46, 47]. In both instances, the patients showed an increase in gut microbiome diversity following FMT, however, metabolic improvements and weight restoration were only observed in one case [46]. Further research is therefore necessary to better understand whether FMT represents a viable treatment option for individuals with AN.

The aim of this pilot study is to assess the feasibility of using FMT to help restore the gut microbiome in individuals with AN. Rather than using invasive FMT administration approaches with limited scalability, our study will employ validated methods for donor microbiome encapsulation [48, 49]. To help boost microbiome diversity, participants will receive an equal number of capsules from four donors who will be selected after extensive health and microbiome screening. Participants will be monitored for adverse events, have their gut microbiome profiled, and be clinically assessed for up to three months post-FMT.

METHODS

Study design

This study is a one-arm, open-label pilot trial investigating the safety, tolerability, and potential of FMT to restore the gut microbiome in young females with AN. The study will be conducted at the Liggins Institute's Clinical Research Unit (University of Auckland), in Auckland, New Zealand.

Participants

We aim to recruit 20 female participants aged 16-25 years who meet the DSM-5 criteria for AN and have a body mass index (BMI) 13-19 kg/m^2 (Table 1). Participants will be recruited through engagement with local eating disorder clinics, the Eating Disorders Association New Zealand (EDANZ), and social media. Study brochures and a detailed participant information sheet will be supplied to potential participants and their caregivers who are interested and considered eligible by their specialist physician. Participants will have the opportunity to ask any questions about the study before they decide to consent. Participants will be able to withdraw from the study at any time.

Table 1. Eligibility criteria for participants and donors.

	Participants	Donors
Inclusion		
	Biological female at birth	Biological female at birth
	16 - 25 years of age	18 - 32 years of age
	BMI 13 - 19 kg/m^2	BMI 18.5 - 25 kg/m^2
	Formal diagnosis of AN by an eating disorder specialist[a]	Total body fat ≤33% (as assessed by DXA)
	Medically stable[b]	Healthy diet (≥4 portions of fruit and/or vegetables/day)
	Able and willing to swallow the treatment capsules	Regular exercise (moderate-to-vigorous physical activity for ≥3.5 hours/week)
	Able and willing to comply with the clinical assessments	Regular bowel habit (passing stools at least once every two days)
Exclusion		
	Known allergies to food and/or common medications	Positive screening test for any transmissible pathogen or multi-drug resistant organism listed in Table 2
	Use of antibiotics or probiotics in the month prior to treatment	Gastrointestinal disease (e.g. inflammatory bowel disease, irritable bowel syndrome, coeliac disease, eosinophilic oesophagitis)
	Regular oral steroid treatment or daily application of potent topical steroids extensively to the body	Metabolic disorder (e.g. diabetes, metabolic syndrome, hypertension, dyslipidemia, dysglycaemia)
	Compromised immune system	Impaired fasting glucose (>5.9 mmol/l) or elevated HbA1c (>41 mmol/mol)
	Any chronic illness affecting gut or metabolic health	Asthma or eczema requiring regular prophylaxis or treatment
	Thoughts of self-harm and/or suicide ideation[c]	Autism spectrum conditions
	Current or planned pregnancy during the course of the study	Previous diagnosis of mental health issues including eating disorders
		Current or past history of malignancy
		Use of oral antibiotics or probiotic supplements in the past 3 months
		Regular binge drinking (>5 alcoholic standards/session at least once/week)
		Past or present use of recreational drugs, tobacco, or vaping
		Current or past pregnancy
		Overseas travel in the past two weeks[d]
		UK residence in 1980-1996 for 6 months or longer[e]

[a] Meeting the DSM-5 criteria, 307.1

[b] In accordance with Starship Children's Hospital's clinical guidelines [50] (i.e., resting heart rate > 50 bpm; no postural drop in blood pressure or rise in heart rate, no electrolyte abnormalities, temperature >35°C and <37.8°C).

[c] Based on response to question 9 of the Patient Health Questionnaire-9 (PHQ9) [51] .

[d] Donors who have travelled overseas will need to wait a minimum period of 2 weeks from their arrival back in New Zealand before donating.

[e] Due to the risk of variant Creutzfeldt-Jakob disease.

Donors

To minimise treatment heterogeneity, we will attempt to use the same four FMT donors throughout the trial. We aim to recruit up to eight female stool donors to ensure we have sufficient reserve donors if one becomes unwell, unavailable, or otherwise ineligible during the study. Donors will be recruited through the University of Auckland's internal email list and via social media advertising. Potential donors will be interviewed over the phone to assess general eligibility criteria (i.e., health and lifestyle parameters) before being invited to our clinic for further screening. We will employ the same donor screening protocol used in our previous FMT trial [52] (Table 1). Donors will be screened to ensure the absence of disease and any transmissible viral, bacterial, or protozoal pathogens (Table 2). Donors will be given a detailed participant information sheet to read, and will have the opportunity to ask any questions about the study before they decide to consent. Donors will be able to withdraw from the study at any time. Any capsules produced prior to withdrawal may be kept for use in the study.

Table 2. Pathogen screening for donors.

	Bacteria	**Parasites**	**Viruses**
Blood	*Treponema pallidum* (syphilis)	*Strongyloides* spp.*	Hepatitis A, B, C HIV
Stool	*Campylobacter* spp. *Clostridioides difficile* toxin A/B Diarrheagenic *Escherichia coli/Shigella:* - Enteroaggregative *E. coli* (EAEC) - Enteroinvasive *E. coli* (EIEC) - Enteropathogenic *E. coli* (EPEC) - Enterotoxigenic *E. coli* (ETEC) - Shiga-like toxin-producing *E. coli* (STEC) *Helicobacter pylori* Multidrug-resistant organisms: - Carbapenem-resistant organisms - ESBL-producing Enterobacteriaceae - Vancomycin-resistant *Enterococcus* spp. *Plesiomonas shigelloides* *Salmonella* spp. *Vibrio* spp. *Yersinia enterocolitica*	*Cryptosporidium* spp. *Cyclospora cayetanensis* *Entamoeba histolytica* *Giardia lamblia* Microscopic examination (ova, cysts, parasites)	Adenovirus F 40/41 Astrovirus Norovirus GI/GII Rotavirus A Sapovirus
Nasal			SARS-CoV-2

* Only performed if the donor has a history of travel to the tropics.

Treatment

All participants will receive the same treatment. We will use a multi-donor FMT approach in which recipients receive 20 capsules containing the gut microbiota from four healthy female donors (5 capsules from each donor). Treatment will be spread over two days (10 capsules/day) or four days (5 capsules/day) depending on the participant's preference. The total FMT dose corresponds to 10 g of concentrated gut microbiota (2.5 g/donor).

FMT capsule preparation

Donors will be asked to visit the Clinical Research Unit every six months to provide fresh stool samples for capsule production. Pathogen screening will be repeated for every capsule batch (Table 2). If multiple stool samples from the same donor are required for one batch of capsules, repeat screening will only be performed if it has been >2 weeks since their last pathogen screen. If any of the four selected donors fail their repeat screening, we will contact and invite one of the reserve donors for rescreening.

We will use validated methods for gut microbiome encapsulation as described previously [52]. Donor stools will be processed individually for encapsulation. Immediately after donation, stool will be blended with 1:2 volumes of 0.9% saline solution and sieved to remove particulate matter. To remove any remaining particulate matter, the faecal slurry will be centrifuged (200x gravity, 5 min, room temperature). The resulting supernatant will be decanted into a fresh tube and centrifuged (5000x gravity, 15 min, room temperature) to concentrate the bacterial pellet. The bacterial pellet will be resuspended at a concentration of 1 g/ml in a cryoprotective solution (15% glycerol, 0.9% saline) and 500 µl aliquots will be dispensed into size 0 delayed release capsules (DRcaps™, Capsugel, Sydney, Australia). The size 0 capsules will be closed and secondarily sealed in size 00 DRcaps™ capsules. DRcaps™ are specifically designed to mask taste and odour, resist stomach acid, and deliver their contents to the proximal bowel [53]. Capsules will be stored at −80°C for up to 6 months.

FMT capsule administration

Treatment appointments will be scheduled for early morning and the participant will need to have fasted overnight for at least 8 hours. Given the high rates of laxative abuse in individuals with AN [54], we will not be performing a laxative bowel cleanse prior to FMT. Depending on the participant's preference, the capsule dose can be spread over two or four consecutive mornings. Capsules will be swallowed with water under direct supervision from a research nurse or clinician. Participants will be asked to postpone their breakfast until one hour after swallowing the capsules to help minimise the length of time the capsules will spend in the stomach.

Study schedule

Participants will have an enrolment appointment where we will explain the study in detail, assess their eligibility, and obtain their written informed consent. During this visit, we will perform a whole-body dual-energy X-ray absorptiometry (DXA) scan and administer the Patient Health Questionnaire 9 (PHQ-9) to confirm they meet the BMI criteria and do not have feelings of self-harm/suicidal ideation. We will also collect a stool sample from the participant during this visit and schedule their baseline assessment for 3 weeks time (Table 3). The first treatment dose will be scheduled on the same day or within a few days of their baseline assessment. Follow-up clinical assessments will be scheduled for 6 and 12 weeks after treatment. Participants will also be asked to collect a stool sample at home 3 weeks after their baseline assessment.

Table 3. Schedule of enrolment, treatment, and clinical assessments for study participants.

	Enrolment *3 weeks before baseline*	**Baseline** clinical assessment	**Treatment** spread over 2 or 4 days	**1-week**	**3-week**	**6-week** clinical assessment	**12-week** clinical assessment
Eligibility screen	✓						
Informed consent	✓						
FMT treatment			✓				
Adverse events			✓	✓	✓	✓	✓
Tolerability questionnaire			✓				
Background questionnaire		✓					
Eating disorder symptoms (EDEQ)		✓				✓	✓
Depression symptoms (PHQ-9)	✓	✓				✓	✓
Anxiety symptoms (GAD-7)		✓				✓	✓
Stool sample	✓	✓			✓	✓	✓
Blood sample		✓				✓	✓
Body composition scan (DXA)	✓						✓

DXA, dual-energy X-ray absorptiometry; EDEQ, Eating Disorder Examination Questionnaire; FMT, faecal microbiome transfer; GAD-7, General Anxiety Disorder 7-item scale; PHQ-9, Patient Health Questionnaire 9.

Data collection and follow-up

Stool sample collection

Stool samples will be collected from participants 3 weeks before treatment, at baseline, and 3, 6, and 12 weeks after treatment to assess changes in the gut microbiome, metabolome, and levels of intestinal inflammation. Where possible, stool samples will be collected on site except for the "3 weeks before" and "3 weeks after" treatment samples which the participant will collect at home. If a participant cannot produce a stool sample during their clinical assessment visit, they will be given a stool collection kit to take home. Collection kits contain a stool catcher, disposable gloves, specimen bag, specimen pottle, DNA/RNA Shield Fecal Collection tube (#R1101, Zymo Research, Irvine, California, USA), and a step-by-step instruction card. If the sample is collected at home, participants will be asked to store their samples within their home freezer until their next appointment or arrange for collection by a member of the research team. Upon receipt, stool samples will be aliquoted and stored in -80°C freezers at Te Ira Kāwai – Auckland Regional Biobank. Stool collected in the DNA/RNA Shield Fecal Collection tube will be reserved for gut microbiome assessment. Stool collected in the specimen pottle (i.e. not containing any stabilization buffer) will be reserved for metabolomics and intestinal inflammation assays (e.g. calprotectin, lactoferrin, and S100A12 [55]).

Gut microbiome profiling

DNA and RNA will be extracted using the ZymoBIOMICS MagBead DNA/RNA kit (Zymo Research, #R2136) according to the manufacturer's instructions with the addition of a bead bashing lysis step (Zymo Research, #S6002-96-3). Shotgun metagenomic and metatranscriptomic sequencing will be performed by a commercial provider using Illumina's paired-end sequencing technology. Sequencing data will be processed as performed previously [49], using bioBakery tools for meta'omic profiling [56]. In particular,

StrainPhlAn [57] will be used to generate single nucleotide polymorphism (SNP) haplotypes representing the dominant strain of any given species within a sample. We will use these SNP haplotypes to compare the genetic similarity of donor and recipient strains before and after treatment to assess the proportion and stability of donor strain engraftment.

Blood sample collection

Blood samples will be collected at baseline, 6 weeks, and 12 weeks after treatment to assess nutritional status and liver/thyroid function (Table 4). A subset of these tests will be performed in real-time throughout the study period for safety monitoring. These tests will also be repeated at the completion of study for evaluation of study outcomes, avoiding any potential batch effects.

Table 4. Blood test schedule for all clinical assessment visits (baseline, week 6, week 12).

	Safety monitoring	Study outcomes
Electrolytes (Sodium, Potassium)	✓	✓
Creatinine	✓	✓
Ferritin	✓	✓
Total protein	✓	✓
Albumin	✓	✓
Alkaline phosphatase (ALP)	✓	✓
Alanine aminotransferase (ALT)	✓	✓
Gamma-glutamyl transferase (GGT)	✓	✓
Aspartate aminotransferase (AST)		✓
Folate		✓
Vitamin B12		✓
Cortisol		✓
Free thyroxine		✓
Thyroid stimulating hormone (TSH)		✓
Serotonin (5-HT)		✓

Anthropometry and body composition

Anthropometric and body composition measurements are potentially triggering for people with AN. Discussions and feedback from eating disorder specialists and recovered individuals have confirmed that regular body weight measurements (specifically standing on scales) throughout the study could cause unnecessary stress for participants given the primary focus of the study is on gut microbiome restoration. However, anthropometry and body composition measurements are important for safety monitoring and detection of potential adverse events. Therefore, a DXA scan will be performed at enrolment and 12 weeks after treatment to assess body weight and composition (including the proportion of lean mass, fat mass, and bone mineral density). We will also measure participants' height barefoot using a wall-mounted stadiometer and combine this information with the DXA-generated body weights to calculate BMI.

Questionnaires

All questionnaires will be completed by the participants online using data capture tools from the web-based research platform, REDCap (Research Electronic Data Capture), hosted in secure servers at the

University of Auckland. At the beginning of the study, we will collect background demographic information from participants including their age, sex assigned at birth, gender identity, self-reported ethnicity, socioeconomic status (based on physical address), age when first diagnosed with AN, and current medications. Socioeconomic status will be estimated using the New Zealand Indices of Multiple Deprivation [58].

After their final dose of capsules, participants will complete a short questionnaire to gather their views and experience of taking the treatment. Specifically, participants will be asked how difficult it was to swallow the capsules, whether they experienced any unpleasant side effects during and/or after swallowing the capsules, and whether they would consider taking the treatment again if it was later shown to be beneficial for recovery.

Participants will also complete three established health questionnaires at baseline, 6 weeks, and 12 weeks after treatment; 1) Eating Disorder Examination Questionnaire (EDEQ v6.0) [59], 2) Patient Health Questionnaire 9 (PHQ-9) for symptoms of depression [51], and 3) General Anxiety Disorder 7-item scale (GAD-7) [60].

Safety monitoring

By adopting strict selection criteria for donors, we will reduce the risk of infection via FMT by minimising the potential transmission of pathogenic organisms. Participants will take each dose of FMT in our clinic under the supervision of a research clinician and/or nurse, where they will remain under close monitoring for at least one hour afterwards. Based on our previous experience and existing evidence, it is unlikely that participants will experience any severe adverse events [35]. However, participants will be instructed to seek immediate medical attention if they develop any severe adverse reactions following treatment. We will contact participants 24 hours after ingestion of each set of capsules, as well as 1, 3, 6, and 12 weeks after treatment to enquire about any adverse side effects. Specifically, participants will be asked to report on the following events: loose or bloody stools, abdominal pain, vomiting, nausea, constipation, flatulence, bloating, fever, malodorous burps, flu-like symptoms, allergic symptoms, appetite, fatigue, and agitation. Adverse events will be graded in accordance with Common Terminology Criteria for Adverse Events v4.0 (CTCAE)[61].

In addition, we will monitor blood markers of nutritional status and liver function (Table 4), any available body weight records as provided by the participant's clinical care team, and questionnaire scores throughout the study in case any of the participants' health starts deteriorating. If the participant answers "several days", "more than half the days" or "nearly every day" to PHQ-9, question 9 "Thoughts that you would be better off dead or of hurting yourself in some way", the research clinician will interview the participant further and provide them with safety management information to take home. Before the participant leaves the clinic, the research clinician will also recommend clinical follow-up and contact the participant's routine care provider and/or the research psychiatrist to ensure additional mental health support is provided.

These clinical and adverse event data will be reviewed by an independent data monitoring committee (DMC) who can decide to stop the trial if the safety of participants is thought to have been compromised. Any serious adverse event or clinical result will be notified immediately to the DMC.

We will strongly advise participants to bring a support person to their study appointments. The support person could be a family member, friend, or member of their support team. Following discussions with our advisers, this person would support the participant during and after the clinic visits, provide comfort and reassurance to the participant throughout the study, and act as an additional point of contact in case the participant becomes uncontactable during the study period.

Outcomes

Primary outcome

- A shift in gut microbiome composition at 3 weeks post-FMT. The shift should exceed the drift in gut microbiome composition measured over the 3 weeks between enrolment and baseline.

Secondary outcomes

- Adverse events associated with FMT treatment
- Proportion of participants who swallow all 20 treatment capsules
- Proportion of participants who would consider having the treatment again if effective
- Gut microbiome composition and functional potential at 6, and 12 weeks post-FMT
- Donor strain engraftment at 3, 6, and 12 weeks post-FMT
- Intestinal inflammation at 6 and 12 weeks post-FMT
- Blood markers of nutritional status and liver/thyroid function at 6 and 12 weeks post-FMT
- Eating disorder symptoms at 6 and 12 weeks post-FMT
- Depression symptoms at 6 and 12 weeks post-FMT
- Anxiety symptoms at 6 and 12 weeks post-FMT
- BMI at 12 weeks post-FMT
- Body composition at 12 weeks post-FMT

Sample size calculation

Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT. Because we do not have a control group to compare against, we will instead collect a stool sample 3 weeks prior to FMT to assess the background drift in the gut microbiome over a 3 week period without any intervention. We will use the Bray-Curtis dissimilarity index to compare gut microbiome composition profiles between sampling time points and test for a difference in these values using a paired t-test. To identify a shift in the gut microbiome above background drift, we will need 18 participants (80% power, alpha = 0.05). This calculation was based on data from our previous FMT trial [35] comparing the gut microbiome shifts between 39 FMT and 44 placebo recipients over 6 weeks (Bray-Curtis dissimilarity to baseline; FMT mean 0.574, Placebo mean 0.416, delta = 0.158, SD = 0.163, t-test p = 2.754e-06). To account for a potential dropout rate of 10%, we aim to recruit 20 participants.

Statistical analyses

We will perform both intention-to-treat and per-protocol analyses. Per-protocol analyses will only include data from those that complete the full treatment dose. Baseline demographics and clinical characteristics will be summarized using descriptive statistics. Gut microbiome shifts will be assessed by calculating the Bray-Curtis dissimilarity index to and from baseline using species-level relative abundance profiles. To assess the primary outcome, a two-sided paired t-test will compare the potential shift in gut microbiome composition 3 weeks before treatment to the shift 3 weeks after treatment. No imputation will be performed for missing data, and statistical significance will be set at $p<0.05$.

Multivariate Association with Linear Models (MaAsLin2) will be used to examine changes in the relative abundances of microbial taxa and their encoded functions in response to treatment. We will also use MaAsLin2 to explore associations between microbiome features and clinical outcomes.

Changes in clinical outcomes from baseline will be assessed using paired t-tests (parametric) or Wilcoxon signed rank tests (non-parametric), as appropriate. However, we acknowledge that we cannot make any treatment efficacy claims based on these paired within-group analyses and without a control group.

Patient and public involvement

This study has been co-designed in consultation with members from the Eating Disorders Association New Zealand (EDANZ) as well as women who have previously recovered from AN. These discussions ensured the study was designed appropriately to minimise participant stress and burden. The study protocol, participant information sheet, and recruitment material have all been reviewed by EDANZ and our study advisors. EDANZ has also offered to support in recruitment for the study by posting on their social media platforms and recommending local clinics and services for us to contact.

ETHICS AND DISSEMINATION

Ethics approval

Ethics approval for the study was granted by the Central Health and Disability Ethics Committee (reference number: 21/CEN/212). The study protocol adheres to the ethical guidelines outlined in the Declaration of Helsinki [62]. All participants will provide written informed consent before participating in the study.

Data management

Each participant in the study will be given a unique de-identified study ID that will be used to label all their data and samples collected throughout the study. All recorded clinical data will be entered and stored in the web-based platform REDCap, which is hosted in secure servers at the University of Auckland. Access to these data will be restricted to the members of the research team. Clinical data will be stored for a minimum period of 10 years. Biological samples (i.e., stool and blood samples) will be securely stored for up to five years in -80°C freezers at Te Ira Kāwai - Auckland Regional Biobank, with access restricted to

members of the research team for the purposes of this study only. All study personnel involved in data and tissue collection will be trained in good clinical practice (GCP), study protocol, and collection requirements. Participants will have the right to access and correct their personal data without being withdrawn from the study. If a participant withdraws from the study, any samples or data collected prior to withdrawal will continue to be used and included in the study.

Data availability

At the completion of the study, the de-identified post-filtered metagenomic sequencing data will be made publicly available on NCBI's sequence read archive (SRA). Note that this data set does not contain human DNA sequences. The de-identified clinical data may be made available for future research upon valid requests to the Liggins Institute Clinical Data Research Hub Data Access Committee. Requestors will need to provide a methodologically sound proposal, obtain appropriate ethics approval, and sign a Data Access Agreement. The Data Access Agreement will include a commitment to using the data only for the specified proposal, not to attempt to identify any individual participants, to securely store and use the data, and to destroy or return the data after completion of the project. Information on data sharing will be provided in the participant information sheet and will be listed in the consent form.

Dissemination

Findings from this study will be communicated to the scientific community through publications in peer-reviewed journals and presentations at relevant conferences and meetings. Study participants will be informed of the study findings as soon as the results become available. Study findings will also be presented to EDANZ and interested participant care providers. In addition, we will communicate our findings with the general public through liaison with the Liggins Institute's communications manager.

ACKNOWLEDGMENTS

The authors would like to thank Nicki Wilson on behalf of Eating Disorders Association New Zealand (EDANZ) as well as Genevieve Mora, Emma Wilson, Rebecca Slykerman, and Russell Walmsley for helpful conversations and their valuable feedback on the study design. The authors would also like to thank the Liggins Institute's Māori Advisory Group and Keri Opai from Wise Group for helping to develop the study framework with Māori perspectives. We are very grateful to the Rockfield Trust for their generous donation to fund this study.

AUTHOR CONTRIBUTIONS

Funding acquisition: WC, JO
Consultation: BW, JD, BA, KL, CC, MD, HT, WC, JO
Study design: BW, JD, BA, KL, RT, CC, MD, TE, TV, HT, WC, JO
Ethics application: BW, JD, BA, KL, TE, TV, HT, WC, JO
Protocol drafting: BW
Protocol revision: BW, JD, BA, KL, RT, CC, MD, TE, TV, HT, WC, JO

CONFLICTS OF INTERESTS

The authors have no conflicts of interest to declare.

FUNDING

This study is fully funded by the Rockfield Trust. The funders had no involvement in the design of the study, and will have no involvement in the collection, analyses, interpretation of data, or in the writing or decision to publish the manuscript on study findings.

REFERENCES

1. Breton, J., Déchelotte, P., & Ribet, D. (2019). Intestinal microbiota and anorexia nervosa. *Clinical Nutrition Experimental*, *28*: 11–21.
2. Arcelus, J., Mitchell, A.J., Wales, J., & Nielsen, S. (2011). Mortality rates in patients with anorexia nervosa and other eating disorders: A meta-analysis of 36 studies. *Archives of General Psychiatry*, *68*(7): 724–731.
3. Fernandez-Aranda, F., Pinheiro, A.P., Tozzi, F., et al (2007). Symptom profile of major depressive disorder in women with eating disorders. *Australian and New Zealand Journal of Psychiatry*, *41*(1): 24–31.
4. Hetterich, L., Mack, I., Giel, K.E., et al (2019). An update on gastrointestinal disturbances in eating disorders. *Molecular and Cellular Endocrinology*, *497*: 110318.
5. Kaye, W.H., Bulik, C.M., Thornton, L., et al (2004). Comorbidity of anxiety disorders with anorexia and bulimia nervosa. *The American Journal of Psychiatry*, *161*(12): 2215–2221.
6. Galmiche, M., Déchelotte, P., Lambert, G., & Tavolacci, M.P. (2019). Prevalence of eating disorders over the 2000-2018 period: A systematic literature review. *American Journal of Clinical Nutrition*, *109*(5): 1402–1413.
7. Rikani, A.A., Choudhry, Z., Choudhry, A.M., et al (2013). A critique of the literature on etiology of eating disorders. *Annals of Neurosciences*, *20*(4): 157–161.
8. Duncan, L., Yilmaz, Z., Gaspar, H., et al (2017). Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. *The American Journal of Psychiatry*, *174*(9): 850–858.
9. Watson, H.J., Yilmaz, Z., Thornton, L.M., et al (2019). Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature Genetics*, *51*(8): 1207–1214.
10. Fetissov, S.O. (2017). Role of the gut microbiota in host appetite control: Bacterial growth to animal feeding behaviour. *Nature Reviews Endocrinology*, *13*(1): 11–25.
11. Visconti, A., Le Roy, C.I., Rosa, F., et al (2019). Interplay between the human gut microbiome and host metabolism. *Nature Communications*, *10*(1): 1–10.
12. Martin, A.M., Sun, E.W., Rogers, G.B., & Keating, D.J. (2019). The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. *Frontiers in Physiology*, *10*: 428.
13. Glenny, E.M., Bulik-Sullivan, E.C., Tang, Q., et al (2017). Eating disorders and the intestinal microbiota: Mechanisms of energy homeostasis and behavioral influence. *Current Psychiatry Reports*, *19*(8): 51.
14. Armougom, F., Henry, M., Vialettes, B., et al (2009). Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. *PLOS ONE*, *4*(9): e7125.
15. Morita, C., Tsuji, H., Hata, T., et al (2015). Gut dysbiosis in patients with anorexia nervosa. *PLOS ONE*, *10*(12): e0145274.
16. Kleiman, S.C., Watson, H.J., Bulik-Sullivan, E.C., et al (2015). The intestinal microbiota in acute

anorexia nervosa and during renourishment: Relationship to depression, anxiety, and eating disorder psychopathology. *Psychosomatic Medicine*, *77*(9): 969–981.

17. Mack, I., Cuntz, U., Grmer, C., et al (2016). Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. *Scientific Reports*, *6*: 26752.
18. Borgo, F., Riva, A., Benetti, A., et al (2017). Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. *PLOS ONE*, *12*(6): e0179739.
19. Mörkl, S., Lackner, S., Müller, W., et al (2017). Gut microbiota and body composition in anorexia nervosa inpatients in comparison to athletes, overweight, obese, and normal weight controls. *International Journal of Eating Disorders*, *50*(12): 1421–1431.
20. Million, M., Angelakis, E., Maraninchi, M., et al (2013). Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. *International Journal of Obesity*, *37*(11): 1460–1466.
21. Camilleri, M. (2019). Leaky gut: mechanisms, measurement and clinical implications in humans. *Gut*, *68*(8): 1516–1526.
22. Seitz, J., Belheouane, M., Schulz, N., et al (2019). The impact of starvation on the microbiome and gut-brain interaction in anorexia nervosa. *Frontiers in Endocrinology*, *10*: 41.
23. Monteleone, P., Carratù, R., Cartenì, M., et al (2004). Intestinal permeability is decreased in anorexia nervosa. *Molecular Psychiatry*, *9*(1): 76–80.
24. Achamrah, N., Nobis, S., Breton, J., et al (2016). Maintaining physical activity during refeeding improves body composition, intestinal hyperpermeability and behavior in anorectic mice. *Scientific Reports*, *6*(1): 1–15.
25. Jésus, P., Ouelaa, W., François, M., et al (2014). Alteration of intestinal barrier function during activity-based anorexia in mice. *Clinical Nutrition*, *33*(6): 1046–1053.
26. Breton, J., Legrand, R., Akkermann, K., et al (2016). Elevated plasma concentrations of bacterial ClpB protein in patients with eating disorders. *International Journal of Eating Disorders*, *49*(8): 805–808.
27. Ghenciulescu, A., Park, R.J., & Burnet, P.W.J. (2021). The gut microbiome in anorexia nervosa: friend or foe? *Frontiers in Psychiatry*, *11*: 611677.
28. Molfino, A., Amabile, M.I., Imbimbo, G., et al (2020). Plasma enterobacterial ClpB levels and ClpB- and α-MSH–reactive immunoglobulins in lung cancer patients with and without anorexia. *Nutrition*, *78*: 110952.
29. Hata, T., Miyata, N., Takakura, S., et al (2019). The gut microbiome derived from anorexia nervosa patients impairs weight gain and behavioral performance in female mice. *Endocrinology*, *160*(10): 2441–2452.
30. Ruusunen, A., Rocks, T., Jacka, F., & Loughman, A. (2019). The gut microbiome in anorexia nervosa: relevance for nutritional rehabilitation. *Psychopharmacology*, *236*(5): 1545–1558.
31. NZ Eating Disorders Clinic Anorexia Nervosa. https://www.nzeatingdisordersclinic.co.nz/eating-disorders/anorexia-nervosa/. Accessed 17 Nov 2020
32. Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014). Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. *Journal of Clinical*

Gastroenterology, *48*(8): 693–702.

33. Yu, E.W., Gao, L., Stastka, P., et al (2020). Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. *PLOS Medicine*, *17*(3): e1003051.

34. Allegretti, J.R., Kassam, Z., Hurtado, J., et al (2021). Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. *Hormones*, *20*: 209–211.

35. Leong, K.S.W., Jayasinghe, T.N., Wilson, B.C., et al (2020). Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. *JAMA Network Open*, *3*(12): e2030415.

36. Vrieze, A., Van Nood, E., Holleman, F., et al (2012). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*, *143*(4): 913-916.e7.

37. Kootte, R.S., Levin, E., Salojärvi, J., et al (2017). Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metabolism*, *26*(4): 611-619.e6.

38. Smits, L.P., Kootte, R.S., Levin, E., et al (2018). Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. *Journal of the American Heart Association*, *7*(7): e008342.

39. de Groot, P., Scheithauer, T., Bakker, G.J., et al (2019). Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut*, *69*(3): 502–512.

40. Paramsothy, S., Paramsothy, R., Rubin, D.T., et al (2017). Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. *Journal of Crohn's and Colitis*, *11*(10): 1180–1199.

41. Ianiro, G., Eusebi, L.H., Black, C.J., et al (2019). Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, *50*(3): 240–248.

42. Kang, D.-W., Adams, J.B., Gregory, A.C., et al (2017). Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome*, *5*(1): 10.

43. Craven, L., Rahman, A., Nair Parvathy, S., et al (2020). Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. *American Journal of Gastroenterology*, *115*(7): 1055–1065.

44. Paramsothy, S., Kamm, M.A., Kaakoush, N.O., et al (2017). Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *The Lancet*, *389*(10075): 1218–1228.

45. Tian, H., Ge, X., Nie, Y., et al (2017). Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. *PLOS ONE*, *12*(2): e0171308.

46. de Clercq, N.C., Frissen, M.N., Davids, M., et al (2019). Weight gain after fecal microbiota

transplantation in a patient with recurrent underweight following clinical recovery from anorexia nervosa. *Psychotherapy and Psychosomatics*, *88*(1): 58–60.

47. Prochazkova, P., Roubalova, R., Dvorak, J., et al (2019). Microbiota, microbial metabolites, and barrier function in a patient with anorexia nervosa after fecal microbiota transplantation. *Microorganisms*, *7*(9): 338.

48. Youngster, I., Russell, G.H., Pindar, C., et al (2014). Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. *JAMA*, *312*(17): 1772.

49. Wilson, B.C., Vatanen, T., Jayasinghe, T.N., et al (2021). Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity. *Microbiome*, *9*(1): 107.

50. Starship (2019). Eating Disorders - management of. https://www.starship.org.nz/guidelines/eating-disorders-management-of/. Accessed 20 May 2021

51. Kroenke, K., Spitzer, R.L., & Williams, J.B.W. (2001). The PHQ-9: Validity of a brief depression severity measure. *Journal of General Internal Medicine*, *16*(9): 606–613.

52. Leong, K.S.W., Jayasinghe, T.N., Derraik, J.G.B., et al (2019). Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents. *BMJ Open*, *9*(4): e026174.

53. DRcaps® Delayed Release Capsules | Capsugel. https://www.capsugel.com/consumer-health-nutrition-products/drcaps-capsules. Accessed 19 Nov 2020

54. Elran-Barak, R., Goldschmidt, A.B., Crow, S.J., et al (2017). Is laxative misuse associated with binge eating? Examination of laxative misuse among individuals seeking treatment for eating disorders. *International Journal of Eating Disorders*, *50*(9): 1114–1118.

55. Lopez, R.N., Leach, S.T., Lemberg, D.A., et al (2017). Fecal biomarkers in inflammatory bowel disease. *Journal of Gastroenterology and Hepatology*, *32*(3): 577–582.

56. McIver, L.J., Abu-Ali, G., Franzosa, E.A., et al (2018). BioBakery: A meta'omic analysis environment. *Bioinformatics*, *34*(7): 1235–1237.

57. Truong, D.T., Tett, A., Pasolli, E., et al (2017). Microbial strain-level population structure & genetic diversity from metagenomes. *Genome Research*, *27*(4): 626–638.

58. Exeter, D.J., Zhao, J., Crengle, S., et al (2017). The New Zealand Indices of Multiple Deprivation (IMD): A new suite of indicators for social and health research in Aotearoa, New Zealand. *PLOS ONE*, *12*(8): e0181260.

59. Fairburn, C.G., & Beglin, S.J. (2008). Eating Disorder Examination Questionnaire (6.0). In Fairburn CG. Cognitive Behavior Therapy and Eating Disorders. Guilford Press, New York

60. Löwe, B., Decker, O., Müller, S., et al (2008). Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. *Medical Care*, *46*(3): 266–274.

61. National Cancer Institute (2009). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

62. World Medical Association (2013). World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA*, *310*(20): 2191–2194.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	14
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 14

Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	1
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	10
Introduction			
Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3,4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	11
Objectives	#7	Specific objectives or hypotheses	11
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4
Methods: Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	4

		be collected. Reference to where list of study sites can be obtained	
Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6,7
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	7, 10
Interventions: adherance	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	7, 10
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	5
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	11
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	4,6

Methods: Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	n/a
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Methods: Data collection, management, and analysis			
Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	8-10

		Reference to where data collection forms can be found, if not in the protocol	
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	12
Methods: Monitoring			
Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	10
Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	10
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events	10

		and other unintended effects of trial interventions or trial conduct	
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	13
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	13
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4,6
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	13
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	13
Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	13
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	10
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the	13

		public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	13
Appendices			
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13

BMJ Open

Protocol for Gut Bugs in Anorexia Nervosa: An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2022-070616.R1
Article Type:	Protocol
Date Submitted by the Author:	10-May-2023
Complete List of Authors:	Wilson, Brooke; The University of Auckland, Liggins Institute Derraik, José; The University of Auckland, Liggins Institute; The University of Auckland, Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences Albert, Benjamin; The University of Auckland, Liggins Institute Leong, Karen; The University of Auckland, Liggins Institute Tweedie-Cullen, Ry; The University of Auckland, Liggins Institute Creagh, Christine; The University of Auckland, Liggins Institute Depczynski, Marysia; The University of Auckland, Liggins Institute Edwards, Taygen; The University of Auckland, Liggins Institute Vatanen, Tommi; The University of Auckland, Liggins Institute; University of Helsinki, Research Program for Clinical and Molecular Metabolism Thabrew, Hiran; The University of Auckland, Psychological Medicine; The University of Auckland, Te Ara Hāro, Centre for Infant, Child and Adolescent Mental Health Cutfield, Wayne; The University of Auckland, Liggins Institute O'Sullivan, Justin ; The University of Auckland, Liggins Institute
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology, Mental health, Pharmacology and therapeutics
Keywords:	Eating disorders < PSYCHIATRY, MICROBIOLOGY, THERAPEUTICS, Transplant medicine < INTERNAL MEDICINE, GASTROENTEROLOGY

Protocol for Gut Bugs in Anorexia Nervosa:

An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa

Brooke C. Wilson[a,], José G. B. Derraik[a,b], Benjamin B. Albert[a], Karen S. W. Leong[a], Ry Y. Tweedie-Cullen[a], Christine Creagh[a], Marysia Depczynski[a], Taygen Edwards[a], Tommi Vatanen[a,c], Hiran Thabrew[d,e], Wayne S. Cutfield[a], Justin M. O'Sullivan[a*]

a. Liggins Institute, University of Auckland, Auckland, New Zealand.
b. Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
c. Research Program for Clinical and Molecular Metabolism, University of Helsinki, Finland
d. Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.
e. Te Ara Hāro, Centre for Infant, Child and Adolescent Mental Health, University of Auckland, Auckland New Zealand.

***Correspondence**
Professor Justin O'Sullivan
Address: Liggins Institute, University of Auckland, Private Bag 92019, Auckland, New Zealand
Email: justin.osullivan@auckland.ac.nz

Version
2

Word count (excludes abstract, tables, acknowledgements, author contributions, COI, references)
4088

ABSTRACT

Introduction: Individuals with anorexia nervosa (AN) harbour distinct gut microbiomes compared to healthy individuals, which are sufficient to induce weight loss and anxiety-like behaviours when transplanted into germ-free mice. We hypothesise that faecal microbiome transfer (FMT) from healthy donors would help restore the gut microbiome of individuals with AN, which in turn, may aid patient recovery.

Methods: We aim to conduct an open-label pilot study in 20 females aged 16-32 years who meet the DSM-5 criteria for AN and have a BMI 13-19 kg/m^2. We will recruit four healthy, lean, female donors, aged 18-32 years, who will undergo extensive clinical screening prior to stool donation. Faecal microbiota will be harvested from donors and double encapsulated in delayed release, acid-resistant capsules. All participants will receive a single course of 20 FMT capsules (five from each donor) which they can choose to take over two or four consecutive days. Stool and blood samples will be collected from participants over a period of three months to assess their gut microbiome profile, metabolome, intestinal inflammation, and nutritional status. Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT (Bray-Curtis dissimilarity). We will also monitor participants' body composition (DXA scans), eating disorder psychopathology, mental health, and assess their views on, and tolerability of, treatment. All adverse events will be recorded and reviewed by an independent data monitoring committee.

Ethics and dissemination: Ethics approval was provided by the Central Health and Disability Ethics Committee (Ministry of Health, New Zealand, 21/CEN/212). Results will be published in peer-reviewed journals and presented to both scientific and consumer group audiences.

Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12621001504808).

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This pilot trial investigates FMT as a therapy for gut microbiome restoration in young women with AN.
- This study has been co-designed in consultation with eating disorder specialists and recovered individuals to minimise participant harm and stress.
- The use of high-resolution shotgun metagenomic sequencing will allow for a comprehensive gut microbiome assessment and longitudinal tracking of donor strain engraftment.
- While we will monitor clinical features of AN throughout the trial, efficacy of FMT on clinical outcomes cannot be assessed due to its design without a control group.
- By focusing on young women with AN, study findings may not necessarily apply to the broader population of individuals with AN.

INTRODUCTION

Anorexia nervosa (AN) is a complex and debilitating eating disorder characterised by extremely restrictive eating behaviour, very low body weight, a fear of weight gain, and body image distortion [1]. AN has the highest mortality rate among psychiatric disorders (standardised mortality ratio of 5.86 [2]) and is often accompanied by comorbidities including anxiety, depression, autoimmune disorders, and functional gastrointestinal disorders [2–5]. AN usually begins in adolescence and is more common in women (lifetime prevalence of 1.4% compared to 0.2% in men [6]). While its exact aetiology is unclear, the development of AN likely stems from both environmental triggers [7] and genetic predisposition [8, 9]. In addition, emerging evidence suggests the gut microbiome might also be involved in AN as an important regulator of appetite, mood, and metabolism [10–13].

Multiple studies have shown that the gut microbiome is perturbed in individuals with AN [14–25]. Early reports suggested AN microbiomes were typically less diverse when compared against healthy age-matched controls [19, 21]. However, more recent observations do not support a simple reduction in microbial diversity being linked to AN [16, 17, 24], but rather, a difference in the relative abundances of specific taxa. In particular, a recent systematic review determined that AN individuals harboured proportionally less fiber-utilising taxa (e.g. *Roseburia* sp.) and more mucin-degrading taxa (e.g. *Akkermansia* sp. and *Methanobrevibacter smithii*) [26]. Degradation of the intestinal mucus lining can lead to increased permeability and translocation of bacterial products into circulation [27, 28], both of which have been observed in AN [29–32].

While the gut microbiome alterations observed in AN are likely a consequence of severe caloric restriction and psychological stress, the gut microbiome itself has also been suggested to play a role in perpetuating symptoms of the disorder [33]. For example, individuals with AN have higher blood levels of caseinolytic-protease-B (ClpB), a protein produced by commensal gut species [32]. ClpB shares homology with the human anorexigenic α-melanocyte-stimulating hormone (a-MSH) and may therefore mimic its function to suppress appetite and increase energy expenditure [34].

A contributory role of the gut microbiome in AN symptomatology was demonstrated when germ-free mice were inoculated with the gut microbiome derived from either healthy human donors or donors with AN [35]. The offspring of mice who received the ‘AN microbiome’ showed reduced body weight and a concomitant reduction in food intake. Interestingly, when the ‘AN microbiome’ mice ate the same amount of food as the ‘healthy microbiome’ mice, they gained less weight suggesting they were less efficient at converting food into body mass [35]. Furthermore, the ‘AN microbiome’ mice had reduced serotonin levels and displayed anxiety-related and compulsive behaviours [35]. Similar weight gain differences were observed in another germ-free mice experiment that utilised both AN and healthy control donors, with differences being linked to altered expression of appetite-suppression and thermogenesis genes [17]. By contrast, another study found no difference in body weight or daily food intake between mice receiving transplantations of AN- or healthy-donor microbiota [36]. Further research is therefore required to determine whether the gut microbiome acts as a potential mediator of disease in AN and is thus a suitable target for therapeutic intervention.

Current treatment approaches for AN are multidisciplinary and focus on nutritional rehabilitation, weight restoration, and cognitive behavioural therapy [37]. However, despite these efforts, approximately 30% of individuals will only partially recover from the disorder, with a further 20% maintaining a chronic course of illness over their lifetime [38]. Even after nutritional interventions and weight restoration, the gut microbiome in individuals with AN remains distinct from that of healthy individuals [19, 20], potentially contributing to relapse of symptoms [33]. Therefore, strategies designed to restore the gut microbiome in AN may be of clinical benefit when used in conjunction with current nutritional rehabilitation therapies, and warrant further investigation.

Faecal microbiome transfer (FMT) involves the transfer of gut microbiota from healthy donors to recipients with gut dysbiosis. This therapy has proven highly effective for treating recurrent *Clostridioides difficile* infections, and can rapidly restore the diversity and functions of the gut microbiome in these patients [39]. FMT has also been trialled in other disorders associated with less severe forms of gut dysbiosis, such as obesity [40–42], metabolic syndrome [43–46], inflammatory bowel disease [47], irritable bowel syndrome [48], and autism [49]. While FMT cannot cure these multi-faceted conditions, its ability to alter the gut microbiome has led to various therapeutic benefits among recipients including improvements in fat distribution [42], metabolic syndrome [42], insulin sensitivity [43, 44], intestinal permeability [50], gut inflammation [51], gastrointestinal symptoms [52], and social behaviours [49].

Given the role of the gut microbiome in regulating appetite, mood, and metabolism [10–12], restoring the gut microbiome in individuals with AN may act as a stepping stone towards improved patient recovery. There have been two published case reports of FMT in patients with AN [53, 54]. In both instances, the patients showed an increase in gut microbiome diversity following FMT, however, metabolic improvements and weight restoration were only observed in one case [53]. Further research is therefore necessary to better understand whether FMT represents a viable treatment option for individuals with AN.

The aim of this pilot study is to assess the feasibility of using FMT to help restore the gut microbiome in individuals with AN. Rather than using invasive FMT administration approaches with limited scalability, our study will employ validated methods for donor microbiome encapsulation [55, 56]. To help boost microbiome diversity, participants will receive an equal number of capsules from four donors who will be selected after extensive health and microbiome screening. Participants will be monitored for adverse events, have their gut microbiome profiled, and be clinically assessed for up to three months post-FMT.

METHODS

Study design

This study is a one-arm, open-label pilot trial investigating the safety, tolerability, and potential of FMT to restore the gut microbiome in young females with AN. The study will be conducted at the Liggins Institute's Clinical Research Unit (University of Auckland), in Auckland, New Zealand.

Participants

We aim to recruit 20 female participants aged 16-32 years who meet the DSM-5 criteria for AN and have a body mass index (BMI) 13-19 kg/m^2 (Table 1). Participants will be recruited through engagement with local eating disorder clinics, the Eating Disorders Association New Zealand (EDANZ), and social media. Study brochures and a detailed participant information sheet will be supplied to potential participants and their caregivers who are interested and considered eligible by their specialist physician. Participants will have the opportunity to ask any questions about the study before they decide to consent. Participants will be able to withdraw from the study at any time.

Table 1. Eligibility criteria for participants and donors.

	Participants	Donors
Inclusion		
	Biological female at birth	Biological female at birth
	16 - 32 years of age	18 - 32 years of age
	BMI 13 - 19 kg/m^2	BMI 18.5 - 25 kg/m^2
	Formal diagnosis of AN by an eating disorder specialist[a]	Total body fat ≤33% (as assessed by DXA)
	Medically stable[b]	Healthy diet (≥4 portions of fruit and/or vegetables/day)
	Able and willing to swallow the treatment capsules	Regular exercise (moderate-to-vigorous physical activity for ≥3.5 hours/week)
	Able and willing to comply with the clinical assessments	Regular bowel habit (passing stools at least once every two days)
Exclusion		
	Known allergies to food and/or common medications	Positive screening test for any transmissible pathogen or multi-drug resistant organism listed in Table 2
	Use of antibiotics or probiotics in the month prior to treatment	Gastrointestinal disease (e.g. inflammatory bowel disease, irritable bowel syndrome, coeliac disease, eosinophilic oesophagitis)
	Regular oral steroid treatment or daily application of potent topical steroids extensively to the body	Metabolic disorder (e.g. diabetes, metabolic syndrome, hypertension, dyslipidemia, dysglycaemia)
	Compromised immune system	Impaired fasting glucose (>5.9 mmol/l) or elevated HbA1c (>41 mmol/mol)
	Any chronic illness affecting gut or metabolic health	Asthma or eczema requiring regular prophylaxis or treatment
	Thoughts of self-harm and/or suicide ideation[c]	Autism spectrum conditions
	Current or planned pregnancy during the course of the study	Previous diagnosis of mental health issues including eating disorders
	Regular laxative use	Current or past history of malignancy
		Use of oral antibiotics or probiotic supplements in the past 3 months
		Regular binge drinking (>5 alcoholic standards/session at least once/week)
		Past or present use of recreational drugs, tobacco, or vaping
		Current or past pregnancy
		Overseas travel in the past two weeks[d]
		UK residence in 1980-1996 for 6 months or longer[e]

[a] Meeting the DSM-5 criteria, 307.1

[b] In accordance with Starship Children's Hospital's clinical guidelines [57] (i.e., resting heart rate > 50 bpm; no postural drop in blood pressure or rise in heart rate, no electrolyte abnormalities, temperature >35°C and <37.8°C).

[c] Based on response to question 9 of the Patient Health Questionnaire-9 (PHQ9) [58] .

[d] Donors who have travelled overseas will need to wait a minimum period of 2 weeks from their arrival back in New Zealand before donating.

[e] Due to the risk of variant Creutzfeldt-Jakob disease.

Donors

To minimise treatment heterogeneity, we will attempt to use the same four FMT donors throughout the trial. We aim to recruit up to eight female stool donors to ensure we have sufficient reserve donors if one becomes unwell, unavailable, or otherwise ineligible during the study. Donors will be recruited through the University of Auckland's internal email list and via social media advertising. Potential donors will be interviewed over the phone to assess general eligibility criteria (i.e. health and lifestyle parameters) before being invited to our clinic for further screening. We will employ the same donor screening protocol used in our previous FMT trial [59] (Table 1). Donors will be screened to ensure the absence of disease and any transmissible viral, bacterial, or protozoal pathogens (Table 2). Donors will be given a detailed participant information sheet to read, and will have the opportunity to ask any questions about the study before they decide to consent. Donors will be able to withdraw from the study at any time. Any capsules produced prior to withdrawal may be kept for use in the study.

Table 2. Pathogen screening for donors.

	Bacteria	**Parasites**	**Viruses**
Blood	*Treponema pallidum* (syphilis)	*Strongyloides* spp.*	Hepatitis A, B, C HIV
Stool	*Campylobacter* spp. *Clostridioides difficile* toxin A/B Diarrheagenic *Escherichia coli/Shigella:* - Enteroaggregative *E. coli* (EAEC) - Enteroinvasive *E. coli* (EIEC) - Enteropathogenic *E. coli* (EPEC) - Enterotoxigenic *E. coli* (ETEC) - Shiga-like toxin-producing *E. coli* (STEC) *Helicobacter pylori* Multidrug-resistant organisms: - Carbapenem-resistant organisms - ESBL-producing Enterobacteriaceae - Vancomycin-resistant *Enterococcus* spp. *Plesiomonas shigelloides* *Salmonella* spp. *Vibrio* spp. *Yersinia enterocolitica*	*Cryptosporidium* spp. *Cyclospora cayetanensis* *Entamoeba histolytica* *Giardia lamblia* Microscopic examination (ova, cysts, parasites)	Adenovirus F 40/41 Astrovirus Norovirus GI/GII Rotavirus A Sapovirus
Nasal			SARS-CoV-2

* Only performed if the donor has a history of travel to the tropics.

Treatment

All participants will receive the same treatment. We will use a multi-donor FMT approach in which recipients receive 20 capsules containing the gut microbiota from four healthy female donors (5 capsules from each donor). Treatment will be spread over two days (10 capsules/day) or four days (5 capsules/day) depending on the participant's preference. The total FMT dose corresponds to 10 g of concentrated gut microbiota (2.5 g/donor).

FMT capsule preparation

Donors will be asked to visit the Clinical Research Unit every six months to provide fresh stool samples for capsule production. Pathogen screening will be repeated for every capsule batch (Table 2). If multiple stool samples from the same donor are required for one batch of capsules, repeat screening will only be performed if it has been >2 weeks since their last pathogen screen. If any of the four selected donors fail their repeat screening, we will contact and invite one of the reserve donors for rescreening.

We will use validated methods for gut microbiome encapsulation as described previously [59]. Donor stools will be processed individually for encapsulation under aerobic conditions. Immediately after donation, stool will be blended with 1:2 volumes of 0.9% saline solution and sieved to remove particulate matter. To remove any remaining particulate matter, the faecal slurry will be centrifuged (200x gravity, 5 min, room temperature). The resulting supernatant will be decanted into a fresh tube and centrifuged (5000x gravity, 15 min, room temperature) to concentrate the bacterial pellet. The bacterial pellet will be resuspended at a concentration of 1 g/ml in a cryoprotective solution (15% glycerol, 0.9% saline) and 500 µl aliquots will be dispensed into size 0 delayed release capsules (DRcaps™, Capsugel, Sydney, Australia). The size 0 capsules will be closed and secondarily sealed in size 00 DRcaps™ capsules. DRcaps™ are specifically designed to mask taste and odour, resist stomach acid, and deliver their contents to the proximal bowel [60]. Capsules will be stored at −80°C for up to 6 months.

FMT capsule administration

Treatment appointments will be scheduled for early morning and the participant will need to have fasted overnight for at least 8 hours. Given the high rates of laxative abuse in individuals with AN [61], we will not be performing a laxative bowel cleanse prior to FMT. Depending on the participant's preference, the capsule dose can be spread over two or four consecutive mornings. Capsules will be swallowed with water under direct supervision from a research nurse or clinician. Participants will be asked to postpone their breakfast until one hour after swallowing the capsules to help minimise the length of time the capsules will spend in the stomach.

Study schedule

Participants will have an enrolment appointment where we will explain the study in detail, assess their eligibility, and obtain their written informed consent. During this visit, we will perform a whole-body dual-energy X-ray absorptiometry (DXA) scan and administer the Patient Health Questionnaire 9 (PHQ-9) to confirm they meet the BMI criteria and do not have feelings of self-harm/suicidal ideation. We will also collect a stool sample from the participant during this visit and schedule their baseline assessment for 3 weeks time (Table 3). The first treatment dose will be given at baseline after all assessments have been completed. Subsequent treatment doses will be scheduled the following consecutive day/s depending on the participant's preference for a 2-day or 4-day treatment schedule. Follow-up clinical assessments will be scheduled for 6 and 12 weeks after baseline. Participants will also be asked to collect a stool sample at home 3 weeks after their baseline assessment.

Table 3. Study Schedule.

	Screening & Enrolment	Baseline & Treatment day 1	Treatment day 2*	48 hours	1-week	3-weeks	6-weeks	12-weeks
Scheduling	*3 weeks before baseline*	*3 weeks after enrolment*	*1 day after baseline*	*2 days after baseline*	*1 week after baseline*	*3 weeks after baseline*	*6 weeks after baseline*	*12 weeks after baseline*
Visit type	*Clinic*	*Clinic*	*Clinic*	*Phone-call*	*Phone-call*	*Phone-call*	*Clinic*	*Clinic*
Eligibility screen	✓							
Informed consent	✓							
FMT treatment		✓	✓					
Adverse events			✓	✓	✓	✓	✓	✓
Tolerability questionnaire			✓					
Background questionnaire		✓						
Eating disorder symptoms (EDEQ)		✓					✓	✓
Depression symptoms (PHQ-9)	✓	✓					✓	✓
Anxiety symptoms (GAD-7)		✓					✓	✓
Stool sample	✓	✓				✓	✓	✓
Blood sample		✓					✓	✓
Body composition scan (DXA)	✓							✓

DXA, dual-energy X-ray absorptiometry; EDEQ, Eating Disorder Examination Questionnaire; FMT, faecal microbiome transfer; GAD-7, General Anxiety Disorder 7-item scale; PHQ-9, Patient Health Questionnaire 9.

*Study timeline is based on a 2-day treatment schedule. If a participant decides to spread their treatment over 4 consecutive days, the tolerability questionnaire will be administered on the final day of treatment (day 4) and the 48 hour phone call will be 24 hours after the final dose of capsules.

Data collection and follow-up

Stool sample collection

Stool samples will be collected from participants 3 weeks before treatment, at baseline, and 3, 6, and 12 weeks after treatment to assess changes in the gut microbiome, metabolome, and levels of intestinal inflammation. Where possible, stool samples will be collected on site except for the "3 weeks before" and "3 weeks after" treatment samples which the participant will collect at home. If a participant cannot produce a stool sample during their clinical assessment visit, they will be given a stool collection kit to take home. Collection kits contain a stool catcher, disposable gloves, specimen bag, specimen pottle, DNA/RNA Shield Fecal Collection tube (#R1101, Zymo Research, Irvine, California, USA), and a step-by-step instruction card. If the sample is collected at home, participants will be asked to store their samples within their home freezer until their next appointment or arrange for collection by a member of the research team. Upon receipt, stool samples will be aliquoted and stored in -80°C freezers at Te Ira Kāwai – Auckland Regional Biobank. Stool collected in the DNA/RNA Shield Fecal Collection tube will be reserved for gut microbiome assessment. Stool collected in the specimen pottle (i.e. not containing any stabilisation buffer) will be reserved for metabolomics and intestinal inflammation assays (e.g. calprotectin, lactoferrin, and S100A12 [62]).

Gut microbiome profiling

DNA and RNA will be extracted using the ZymoBIOMICS MagBead DNA/RNA kit (Zymo Research, #R2136) according to the manufacturer's instructions with the addition of a bead bashing lysis step (Zymo Research, #S6002-96-3). Shotgun metagenomic and metatranscriptomic sequencing will be performed by a commercial provider using Illumina's paired-end sequencing technology. Sequencing data will be processed as performed previously [56], using bioBakery tools for meta'omic profiling [63]. In particular, StrainPhlAn [64] will be used to generate single nucleotide polymorphism (SNP) haplotypes representing the dominant strain of any given species within a sample. We will use these SNP haplotypes to compare the genetic similarity of donor and recipient strains before and after treatment to assess the proportion and stability of donor strain engraftment.

Blood sample collection

Blood samples will be collected at baseline, 6 weeks, and 12 weeks after treatment to assess nutritional status, inflammation, and liver/thyroid function (Table 4). A subset of these tests will be performed in real-time throughout the study period for safety monitoring. These tests will also be repeated at the completion of study for evaluation of study outcomes, avoiding any potential batch effects.

Table 4. Blood test schedule for all clinical assessment visits (baseline, week 6, week 12).

	Safety monitoring	Study outcomes
Electrolytes (Sodium, Potassium)	✓	✓
Creatinine	✓	✓
Ferritin	✓	✓
Total protein	✓	✓
Albumin	✓	✓

Alkaline phosphatase (ALP)	✓	✓
Alanine aminotransferase (ALT)	✓	✓
Gamma-glutamyl transferase (GGT)	✓	✓
Aspartate aminotransferase (AST)		✓
C-reactive protein (CRP)		✓
Cholinesterase		✓
Folate		✓
Vitamin B12		✓
Cortisol		✓
Free thyroxine		✓
Thyroid stimulating hormone (TSH)		✓
Serotonin (5-HT)		✓

Anthropometry and body composition

Anthropometric and body composition measurements are potentially triggering for people with AN. Discussions and feedback from eating disorder specialists and recovered individuals have confirmed that regular body weight measurements (specifically standing on scales) throughout the study could cause unnecessary stress for participants given the primary focus of the study is on gut microbiome restoration. However, anthropometry and body composition measurements are important for safety monitoring and detection of potential adverse events. Therefore, a DXA scan will be performed at enrolment and 12 weeks after treatment to assess body weight and composition (including the proportion of lean mass, fat mass, and bone mineral density). We will also measure participants' height barefoot using a wall-mounted stadiometer and combine this information with the DXA-generated body weights to calculate BMI.

Questionnaires

All questionnaires will be completed by the participants online using data capture tools from the web-based research platform, REDCap (Research Electronic Data Capture), hosted in secure servers at the University of Auckland. At the beginning of the study, we will collect background demographic information from participants including their age, sex assigned at birth, gender identity, self-reported ethnicity, socioeconomic status (based on physical address), age when first diagnosed with AN, and current medications. Socioeconomic status will be estimated using the New Zealand Indices of Multiple Deprivation [65].

After their final dose of capsules, participants will complete a short questionnaire to gather their views and experience of taking the treatment. Specifically, participants will be asked how difficult it was to swallow the capsules, whether they experienced any unpleasant side effects during and/or after swallowing the capsules, and whether they would consider taking the treatment again if it was later shown to be beneficial for recovery.

Participants will also complete three established health questionnaires at baseline, 6 weeks, and 12 weeks after treatment: 1) Eating Disorder Examination Questionnaire (EDEQ v6.0) [66], 2) Patient Health Questionnaire 9 (PHQ-9) for symptoms of depression [58], and 3) General Anxiety Disorder 7-item scale (GAD-7) [67].

Safety monitoring

By adopting strict selection criteria for donors, we will reduce the risk of infection via FMT by minimising the potential transmission of pathogenic organisms. Participants will take each dose of FMT in our clinic under the supervision of a research clinician and/or nurse, where they will remain under close monitoring for at least one hour afterwards. Based on our previous experience and existing evidence, it is unlikely that participants will experience any severe adverse events [42]. However, participants will be instructed to seek immediate medical attention if they develop any severe adverse reactions following treatment. We will contact participants 24 hours after ingestion of each set of capsules, as well as 1, 3, 6, and 12 weeks after treatment to enquire about any adverse side effects. Specifically, participants will be asked to report on the following events: loose or bloody stools, abdominal pain, vomiting, nausea, constipation, flatulence, bloating, fever, malodorous burps, flu-like symptoms, allergic symptoms, appetite, fatigue, and agitation. Adverse events will be graded in accordance with Common Terminology Criteria for Adverse Events v4.0 (CTCAE) [68].

In addition, we will monitor blood markers of nutritional status and liver function (Table 4), any available body weight records as provided by the participant's clinical care team, and questionnaire scores throughout the study in case any of the participants' health starts deteriorating. If the participant answers "several days", "more than half the days" or "nearly every day" to PHQ-9, question 9 "Thoughts that you would be better off dead or of hurting yourself in some way", the research clinician will interview the participant further and provide them with safety management information to take home. Before the participant leaves the clinic, the research clinician will also recommend clinical follow-up and contact the participant's routine care provider and/or the research psychiatrist to ensure additional mental health support is provided.

These clinical and adverse event data will be reviewed by an independent data monitoring committee (DMC) who can decide to stop the trial if the safety of participants is thought to have been compromised. Any serious adverse event or clinical result will be notified immediately to the DMC.

We will strongly advise participants to bring a support person to their study appointments. The support person could be a family member, friend, or member of their support team. Following discussions with our advisers, this person would support the participant during and after the clinic visits, provide comfort and reassurance to the participant throughout the study, and act as an additional point of contact in case the participant becomes uncontactable during the study period.

Outcomes

Primary outcome

- A shift in gut microbiome composition at 3 weeks post-FMT (Bray-Curtis dissimilarity). The shift should exceed the drift in gut microbiome composition measured over the 3 weeks between enrolment and baseline.

Secondary outcomes

- Adverse events associated with FMT treatment
- Proportion of participants who swallow all 20 treatment capsules
- Proportion of participants who would consider having the treatment again if effective
- Gut microbiome diversity, composition and functional potential at 6, and 12 weeks post-FMT
- Donor strain engraftment at 3, 6, and 12 weeks post-FMT
- Intestinal inflammation at 6 and 12 weeks post-FMT
- Blood markers of nutritional status and liver/thyroid function at 6 and 12 weeks post-FMT
- Eating disorder symptoms at 6 and 12 weeks post-FMT
- Depression symptoms at 6 and 12 weeks post-FMT
- Anxiety symptoms at 6 and 12 weeks post-FMT
- BMI at 12 weeks post-FMT
- Body composition at 12 weeks post-FMT

Sample size calculation

Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT. Because we do not have a control group to compare against, we will instead collect a stool sample 3 weeks prior to FMT to assess the background drift in the gut microbiome over a 3 week period without any intervention. We will use the Bray-Curtis dissimilarity index to compare gut microbiome composition profiles between sampling time points and test for a difference in these values using a paired t-test. To identify a shift in the gut microbiome above background drift, we will need 18 participants (80% power, alpha = 0.05). This calculation was based on data from our previous FMT trial [42] comparing the gut microbiome shifts between 39 FMT and 44 placebo recipients over 6 weeks (Bray-Curtis dissimilarity to baseline; FMT mean 0.574, Placebo mean 0.416, delta = 0.158, SD = 0.163, t-test p = 2.754e-06). To account for a potential dropout rate of 10%, we aim to recruit at least 20 participants who complete treatment and the primary outcome assessment.

Statistical analyses

We will perform both intention-to-treat and per-protocol analyses. Per-protocol analyses will only include data from those that complete the full treatment dose. Baseline demographics and clinical characteristics will be summarised using descriptive statistics. Gut microbiome shifts will be assessed by calculating the Bray-Curtis dissimilarity index to and from baseline using species-level relative abundance profiles. To assess the primary outcome, a two-sided paired t-test will compare the potential shift in gut microbiome composition 3 weeks before treatment to the shift 3 weeks after treatment. No imputation will be performed for missing data, and statistical significance will be set at $p<0.05$.

Multivariate Association with Linear Models (MaAsLin2) will be used to examine changes in the relative abundances of microbial taxa and their encoded functions in response to treatment. We will also use MaAsLin2 to explore associations between microbiome features and clinical outcomes.

Changes in clinical outcomes from baseline will be assessed using paired t-tests (parametric) or Wilcoxon signed rank tests (non-parametric), as appropriate. However, we acknowledge that we cannot make any treatment efficacy claims based on these paired within-group analyses and without a control group.

Patient and public involvement

This study has been co-designed in consultation with members from the Eating Disorders Association New Zealand (EDANZ) as well as women who have previously recovered from AN. These discussions ensured the study was designed appropriately to minimise participant stress and burden. The study protocol, participant information sheet, and recruitment material have all been reviewed by EDANZ and our study advisors. EDANZ has also offered to support in recruitment for the study by posting on their social media platforms and recommending local clinics and services for us to contact.

ETHICS AND DISSEMINATION

Ethics approval

Ethics approval for the study was granted by the Central Health and Disability Ethics Committee (reference number: 21/CEN/212). The study protocol adheres to the ethical guidelines outlined in the Declaration of Helsinki [69]. All participants will provide written informed consent before participating in the study.

Data management

Each participant in the study will be given a unique de-identified study ID that will be used to label all their data and samples collected throughout the study. All recorded clinical data will be entered and stored in the web-based platform REDCap, which is hosted in secure servers at the University of Auckland. Access to these data will be restricted to the members of the research team. Clinical data will be stored for a minimum period of 10 years. Biological samples (i.e., stool and blood samples) will be securely stored for up to five years in -80°C freezers at Te Ira Kāwai - Auckland Regional Biobank, with access restricted to members of the research team for the purposes of this study only. All study personnel involved in data and tissue collection will be trained in good clinical practice (GCP), study protocol, and collection requirements. Participants will have the right to access and correct their personal data without being withdrawn from the study. If a participant withdraws from the study, any samples or data collected prior to withdrawal will continue to be used and included in the study.

Data availability

At the completion of the study, the de-identified post-filtered metagenomic sequencing data will be made publicly available on NCBI's sequence read archive (SRA). Note that this data set does not contain human DNA sequences. The de-identified clinical data may be made available for future research upon valid requests to the Liggins Institute Clinical Data Research Hub Data Access Committee. Requestors will need to provide a methodologically sound proposal, obtain appropriate ethics approval, and sign a Data Access Agreement. The Data Access Agreement will include a commitment to using the data only for the

specified proposal, not to attempt to identify any individual participants, to securely store and use the data, and to destroy or return the data after completion of the project. Information on data sharing will be provided in the participant information sheet and will be listed in the consent form.

Dissemination

Findings from this study will be communicated to the scientific community through publications in peer-reviewed journals and presentations at relevant conferences and meetings. Study participants will be informed of the study findings as soon as the results become available. Study findings will also be presented to EDANZ and interested participant care providers. In addition, we will communicate our findings with the general public through liaison with the Liggins Institute's communications manager.

ACKNOWLEDGMENTS

The authors would like to thank Nicki Wilson on behalf of Eating Disorders Association New Zealand (EDANZ) as well as Genevieve Mora, Emma Wilson, Rebecca Slykerman, and Russell Walmsley for helpful conversations and their valuable feedback on the study design. The authors would also like to thank the Liggins Institute's Māori Advisory Group and Keri Opai from Wise Group for helping to develop the study framework with Māori perspectives. We are very grateful to the Rockfield Trust for their generous donation to fund this study.

AUTHOR CONTRIBUTIONS

Funding acquisition: WC, JO
Consultation: BW, JD, BA, KL, CC, MD, HT, WC, JO
Study design: BW, JD, BA, KL, RTC, CC, MD, TE, TV, HT, WC, JO
Ethics application: BW, JD, BA, KL, TE, TV, HT, WC, JO
Protocol drafting: BW
Protocol revision: BW, JD, BA, KL, RTC, CC, MD, TE, TV, HT, WC, JO

CONFLICTS OF INTERESTS

The authors have no conflicts of interest to declare.

FUNDING

This study is fully funded by the Rockfield Trust (Award/Grant no: NA). The funders had no involvement in the design of the study, and will have no involvement in the collection, analyses, interpretation of data, or in the writing or decision to publish the manuscript on study findings.

REFERENCES

1. Breton, J., Déchelotte, P., & Ribet, D. (2019). Intestinal microbiota and anorexia nervosa. *Clinical Nutrition Experimental*, *28*: 11–21.
2. Arcelus, J., Mitchell, A.J., Wales, J., & Nielsen, S. (2011). Mortality rates in patients with anorexia nervosa and other eating disorders: A meta-analysis of 36 studies. *Archives of General Psychiatry*, *68*(7): 724–731.
3. Fernandez-Aranda, F., Pinheiro, A.P., Tozzi, F., et al (2007). Symptom profile of major depressive disorder in women with eating disorders. *Australian and New Zealand Journal of Psychiatry*, *41*(1): 24–31.
4. Hetterich, L., Mack, I., Giel, K.E., et al (2019). An update on gastrointestinal disturbances in eating disorders. *Molecular and Cellular Endocrinology*, *497*: 110318.
5. Kaye, W.H., Bulik, C.M., Thornton, L., et al (2004). Comorbidity of anxiety disorders with anorexia and bulimia nervosa. *The American Journal of Psychiatry*, *161*(12): 2215–2221.
6. Galmiche, M., Déchelotte, P., Lambert, G., & Tavolacci, M.P. (2019). Prevalence of eating disorders over the 2000-2018 period: A systematic literature review. *American Journal of Clinical Nutrition*, *109*(5): 1402–1413.
7. Rikani, A.A., Choudhry, Z., Choudhry, A.M., et al (2013). A critique of the literature on etiology of eating disorders. *Annals of Neurosciences*, *20*(4): 157–161.
8. Duncan, L., Yilmaz, Z., Gaspar, H., et al (2017). Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. *The American Journal of Psychiatry*, *174*(9): 850–858.
9. Watson, H.J., Yilmaz, Z., Thornton, L.M., et al (2019). Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature Genetics*, *51*(8): 1207–1214.
10. Fetissov, S.O. (2017). Role of the gut microbiota in host appetite control: Bacterial growth to animal feeding behaviour. *Nature Reviews Endocrinology*, *13*(1): 11–25.
11. Visconti, A., Le Roy, C.I., Rosa, F., et al (2019). Interplay between the human gut microbiome and host metabolism. *Nature Communications*, *10*(1): 1–10.
12. Martin, A.M., Sun, E.W., Rogers, G.B., & Keating, D.J. (2019). The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. *Frontiers in Physiology*, *10*: 428.
13. Glenny, E.M., Bulik-Sullivan, E.C., Tang, Q., et al (2017). Eating disorders and the intestinal microbiota: Mechanisms of energy homeostasis and behavioral influence. *Current Psychiatry Reports*, *19*(8): 51.
14. Armougom, F., Henry, M., Vialettes, B., et al (2009). Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. *PLOS ONE*, *4*(9): e7125.
15. Million, M., Angelakis, E., Maraninchi, M., et al (2013). Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. *International Journal of Obesity*, *37*(11): 1460–1466.

16. Prochazkova, P., Roubalova, R., Dvorak, J., et al (2021). The intestinal microbiota and metabolites in patients with anorexia nervosa. *Gut Microbes*, *13*(1): 1–25.
17. Fan, Y., Støving, R.K., Berreira Ibraim, S., et al (2023). The gut microbiota contributes to the pathogenesis of anorexia nervosa in humans and mice. *Nature Microbiology*, : 1–16.
18. Morita, C., Tsuji, H., Hata, T., et al (2015). Gut dysbiosis in patients with anorexia nervosa. *PLOS ONE*, *10*(12): e0145274.
19. Kleiman, S.C., Watson, H.J., Bulik-Sullivan, E.C., et al (2015). The intestinal microbiota in acute anorexia nervosa and during renourishment: Relationship to depression, anxiety, and eating disorder psychopathology. *Psychosomatic Medicine*, *77*(9): 969–981.
20. Mack, I., Cuntz, U., Grmer, C., et al (2016). Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. *Scientific Reports*, *6*: 26752.
21. Mörkl, S., Lackner, S., Müller, W., et al (2017). Gut microbiota and body composition in anorexia nervosa inpatients in comparison to athletes, overweight, obese, and normal weight controls. *International Journal of Eating Disorders*, *50*(12): 1421–1431.
22. Borgo, F., Riva, A., Benetti, A., et al (2017). Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. *PLOS ONE*, *12*(6): e0179739.
23. Hanachi, M., Manichanh, C., Schoenenberger, A., et al (2019). Altered host-gut microbes symbiosis in severely malnourished anorexia nervosa (AN) patients undergoing enteral nutrition: An explicative factor of functional intestinal disorders? *Clinical Nutrition*, *38*(5): 2304–2310.
24. Schulz, N., Belheouane, M., Dahmen, B., et al (2021). Gut microbiota alteration in adolescent anorexia nervosa does not normalize with short-term weight restoration. *International Journal of Eating Disorders*, *54*(6): 969–980.
25. Monteleone, A.M., Troisi, J., Fasano, A., et al (2021). Multi-omics data integration in anorexia nervosa patients before and after weight regain: A microbiome-metabolomics investigation. *Clinical Nutrition*, *40*(3): 1137–1146.
26. Di Lodovico, L., Mondot, S., Doré, J., et al (2021). Anorexia nervosa and gut microbiota: A systematic review and quantitative synthesis of pooled microbiological data. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *106*: 110114.
27. Camilleri, M. (2019). Leaky gut: mechanisms, measurement and clinical implications in humans. *Gut*, *68*(8): 1516–1526.
28. Seitz, J., Belheouane, M., Schulz, N., et al (2019). The impact of starvation on the microbiome and gut-brain interaction in anorexia nervosa. *Frontiers in Endocrinology*, *10*: 41.
29. Monteleone, P., Carratù, R., Cartenì, M., et al (2004). Intestinal permeability is decreased in anorexia nervosa. *Molecular Psychiatry*, *9*(1): 76–80.
30. Achamrah, N., Nobis, S., Breton, J., et al (2016). Maintaining physical activity during refeeding improves body composition, intestinal hyperpermeability and behavior in anorectic mice. *Scientific Reports*, *6*(1): 1–15.
31. Jésus, P., Ouelaa, W., François, M., et al (2014). Alteration of intestinal barrier function during activity-based anorexia in mice. *Clinical Nutrition*, *33*(6): 1046–1053.
32. Breton, J., Legrand, R., Akkermann, K., et al (2016). Elevated plasma concentrations of bacterial

ClpB protein in patients with eating disorders. *International Journal of Eating Disorders*, *49*(8): 805–808.

33. Ghenciulescu, A., Park, R.J., & Burnet, P.W.J. (2021). The gut microbiome in anorexia nervosa: friend or foe? *Frontiers in Psychiatry*, *11*: 611677.

34. Molfino, A., Amabile, M.I., Imbimbo, G., et al (2020). Plasma enterobacterial ClpB levels and ClpB- and α-MSH–reactive immunoglobulins in lung cancer patients with and without anorexia. *Nutrition*, *78*: 110952.

35. Hata, T., Miyata, N., Takakura, S., et al (2019). The gut microbiome derived from anorexia nervosa patients impairs weight gain and behavioral performance in female mice. *Endocrinology*, *160*(10): 2441–2452.

36. Glenny, E.M., Fouladi, F., Thomas, S.A., et al (2021). Gut microbial communities from patients with anorexia nervosa do not influence body weight in recipient germ-free mice. *Gut microbes*, *13*(1): 1–15.

37. Ruusunen, A., Rocks, T., Jacka, F., & Loughman, A. (2019). The gut microbiome in anorexia nervosa: relevance for nutritional rehabilitation. *Psychopharmacology*, *236*(5): 1545–1558.

38. NZ Eating Disorders Clinic Anorexia Nervosa. https://www.nzeatingdisordersclinic.co.nz/eating-disorders/anorexia-nervosa/. Accessed 17 Nov 2020

39. Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014). Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. *Journal of Clinical Gastroenterology*, *48*(8): 693–702.

40. Yu, E.W., Gao, L., Stastka, P., et al (2020). Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. *PLOS Medicine*, *17*(3): e1003051.

41. Allegretti, J.R., Kassam, Z., Hurtado, J., et al (2021). Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. *Hormones*, *20*: 209–211.

42. Leong, K.S.W., Jayasinghe, T.N., Wilson, B.C., et al (2020). Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. *JAMA Network Open*, *3*(12): e2030415.

43. Vrieze, A., Van Nood, E., Holleman, F., et al (2012). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*, *143*(4): 913-916.e7.

44. Kootte, R.S., Levin, E., Salojärvi, J., et al (2017). Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metabolism*, *26*(4): 611-619.e6.

45. Smits, L.P., Kootte, R.S., Levin, E., et al (2018). Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. *Journal of the American Heart Association*, *7*(7): e008342.

46. de Groot, P., Scheithauer, T., Bakker, G.J., et al (2019). Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut*, *69*(3): 502–512.

47. Paramsothy, S., Paramsothy, R., Rubin, D.T., et al (2017). Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. *Journal of Crohn's and Colitis*, *11*(10): 1180–1199.
48. Ianiro, G., Eusebi, L.H., Black, C.J., et al (2019). Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, *50*(3): 240–248.
49. Kang, D.-W., Adams, J.B., Gregory, A.C., et al (2017). Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome*, *5*(1): 10.
50. Craven, L., Rahman, A., Nair Parvathy, S., et al (2020). Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. *American Journal of Gastroenterology*, *115*(7): 1055–1065.
51. Paramsothy, S., Kamm, M.A., Kaakoush, N.O., et al (2017). Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *The Lancet*, *389*(10075): 1218–1228.
52. Tian, H., Ge, X., Nie, Y., et al (2017). Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. *PLOS ONE*, *12*(2): e0171308.
53. de Clercq, N.C., Frissen, M.N., Davids, M., et al (2019). Weight gain after fecal microbiota transplantation in a patient with recurrent underweight following clinical recovery from anorexia nervosa. *Psychotherapy and Psychosomatics*, *88*(1): 58–60.
54. Prochazkova, P., Roubalova, R., Dvorak, J., et al (2019). Microbiota, microbial metabolites, and barrier function in a patient with anorexia nervosa after fecal microbiota transplantation. *Microorganisms*, *7*(9): 338.
55. Youngster, I., Russell, G.H., Pindar, C., et al (2014). Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. *JAMA*, *312*(17): 1772.
56. Wilson, B.C., Vatanen, T., Jayasinghe, T.N., et al (2021). Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity. *Microbiome*, *9*(1): 107.
57. Starship (2019). Eating Disorders - management of. https://www.starship.org.nz/guidelines/eating-disorders-management-of/. Accessed 20 May 2021
58. Kroenke, K., Spitzer, R.L., & Williams, J.B.W. (2001). The PHQ-9: Validity of a brief depression severity measure. *Journal of General Internal Medicine*, *16*(9): 606–613.
59. Leong, K.S.W., Jayasinghe, T.N., Derraik, J.G.B., et al (2019). Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents. *BMJ Open*, *9*(4): e026174.
60. DRcaps® Delayed Release Capsules | Capsugel. https://www.capsugel.com/consumer-health-nutrition-products/drcaps-capsules. Accessed 19 Nov 2020
61. Elran-Barak, R., Goldschmidt, A.B., Crow, S.J., et al (2017). Is laxative misuse associated with binge eating? Examination of laxative misuse among individuals seeking treatment for eating

disorders. *International Journal of Eating Disorders*, *50*(9): 1114–1118.

62. Lopez, R.N., Leach, S.T., Lemberg, D.A., et al (2017). Fecal biomarkers in inflammatory bowel disease. *Journal of Gastroenterology and Hepatology*, *32*(3): 577–582.

63. McIver, L.J., Abu-Ali, G., Franzosa, E.A., et al (2018). BioBakery: A meta'omic analysis environment. *Bioinformatics*, *34*(7): 1235–1237.

64. Truong, D.T., Tett, A., Pasolli, E., et al (2017). Microbial strain-level population structure & genetic diversity from metagenomes. *Genome Research*, *27*(4): 626–638.

65. Exeter, D.J., Zhao, J., Crengle, S., et al (2017). The New Zealand Indices of Multiple Deprivation (IMD): A new suite of indicators for social and health research in Aotearoa, New Zealand. *PLOS ONE*, *12*(8): e0181260.

66. Fairburn, C.G., & Beglin, S.J. (2008). Eating Disorder Examination Questionnaire (6.0). In Fairburn CG. Cognitive Behavior Therapy and Eating Disorders. Guilford Press, New York

67. Löwe, B., Decker, O., Müller, S., et al (2008). Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. *Medical Care*, *46*(3): 266–274.

68. National Cancer Institute (2009). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

69. World Medical Association (2013). World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA*, *310*(20): 2191–2194.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	14
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 14

Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	1
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	10
Introduction			
Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3,4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	11
Objectives	#7	Specific objectives or hypotheses	11
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4
Methods: Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	4

		be collected. Reference to where list of study sites can be obtained	
Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6,7
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	7, 10
Interventions: adherance	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	7, 10
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	5
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	11
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	4,6

Methods: Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	n/a
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Methods: Data collection, management, and analysis			
Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	8-10

		Reference to where data collection forms can be found, if not in the protocol	
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	12
Methods: Monitoring			
Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	10
Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	10
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events	10

		and other unintended effects of trial interventions or trial conduct	
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	13
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	13
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	4,6
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	13
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	13
Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	13
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	10
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the	13

		public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	13
Appendices			
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13